Actionable Driver Events in Small Cell Lung Cancer
Small cell lung cancer (SCLC) stands out as the most aggressive form of lung cancer, characterized by an extremely high proliferation rate and a very poor prognosis, with a 5-year survival rate that falls below 7%. Approximately two-thirds of patients receive their diagnosis when the disease has alr...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/25/1/105 |
| _version_ | 1797358722913140736 |
|---|---|
| author | Mirian Gutiérrez Irene Zamora Michael R. Freeman Ignacio J. Encío Mirja Rotinen |
| author_facet | Mirian Gutiérrez Irene Zamora Michael R. Freeman Ignacio J. Encío Mirja Rotinen |
| author_sort | Mirian Gutiérrez |
| collection | DOAJ |
| description | Small cell lung cancer (SCLC) stands out as the most aggressive form of lung cancer, characterized by an extremely high proliferation rate and a very poor prognosis, with a 5-year survival rate that falls below 7%. Approximately two-thirds of patients receive their diagnosis when the disease has already reached a metastatic or extensive stage, leaving chemotherapy as the remaining first-line treatment option. Other than the recent advances in immunotherapy, which have shown moderate results, SCLC patients cannot yet benefit from any approved targeted therapy, meaning that this cancer remains treated as a uniform entity, disregarding intra- or inter-tumoral heterogeneity. Continuous efforts and technological improvements have enabled the identification of new potential targets that could be used to implement novel therapeutic strategies. In this review, we provide an overview of the most recent approaches for SCLC treatment, providing an extensive compilation of the targeted therapies that are currently under clinical evaluation and inhibitor molecules with promising results in vitro and in vivo. |
| first_indexed | 2024-03-08T15:06:16Z |
| format | Article |
| id | doaj.art-49abe58d12744fe9a16fbfbfbd224a92 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-08T15:06:16Z |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-49abe58d12744fe9a16fbfbfbd224a922024-01-10T14:58:11ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-12-0125110510.3390/ijms25010105Actionable Driver Events in Small Cell Lung CancerMirian Gutiérrez0Irene Zamora1Michael R. Freeman2Ignacio J. Encío3Mirja Rotinen4Department of Health Sciences, Public University of Navarre, 31008 Pamplona, SpainDepartment of Health Sciences, Public University of Navarre, 31008 Pamplona, SpainDepartments of Urology and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USADepartment of Health Sciences, Public University of Navarre, 31008 Pamplona, SpainDepartment of Health Sciences, Public University of Navarre, 31008 Pamplona, SpainSmall cell lung cancer (SCLC) stands out as the most aggressive form of lung cancer, characterized by an extremely high proliferation rate and a very poor prognosis, with a 5-year survival rate that falls below 7%. Approximately two-thirds of patients receive their diagnosis when the disease has already reached a metastatic or extensive stage, leaving chemotherapy as the remaining first-line treatment option. Other than the recent advances in immunotherapy, which have shown moderate results, SCLC patients cannot yet benefit from any approved targeted therapy, meaning that this cancer remains treated as a uniform entity, disregarding intra- or inter-tumoral heterogeneity. Continuous efforts and technological improvements have enabled the identification of new potential targets that could be used to implement novel therapeutic strategies. In this review, we provide an overview of the most recent approaches for SCLC treatment, providing an extensive compilation of the targeted therapies that are currently under clinical evaluation and inhibitor molecules with promising results in vitro and in vivo.https://www.mdpi.com/1422-0067/25/1/105small cell lung cancerheterogeneitytargeted therapyinhibitor moleculesclinical vulnerability |
| spellingShingle | Mirian Gutiérrez Irene Zamora Michael R. Freeman Ignacio J. Encío Mirja Rotinen Actionable Driver Events in Small Cell Lung Cancer International Journal of Molecular Sciences small cell lung cancer heterogeneity targeted therapy inhibitor molecules clinical vulnerability |
| title | Actionable Driver Events in Small Cell Lung Cancer |
| title_full | Actionable Driver Events in Small Cell Lung Cancer |
| title_fullStr | Actionable Driver Events in Small Cell Lung Cancer |
| title_full_unstemmed | Actionable Driver Events in Small Cell Lung Cancer |
| title_short | Actionable Driver Events in Small Cell Lung Cancer |
| title_sort | actionable driver events in small cell lung cancer |
| topic | small cell lung cancer heterogeneity targeted therapy inhibitor molecules clinical vulnerability |
| url | https://www.mdpi.com/1422-0067/25/1/105 |
| work_keys_str_mv | AT miriangutierrez actionabledrivereventsinsmallcelllungcancer AT irenezamora actionabledrivereventsinsmallcelllungcancer AT michaelrfreeman actionabledrivereventsinsmallcelllungcancer AT ignaciojencio actionabledrivereventsinsmallcelllungcancer AT mirjarotinen actionabledrivereventsinsmallcelllungcancer |